Safety and Efficacy of Elagolix in Pre-Menopausal Women With Heavy Uterine Bleeding and Uterine Fibroids
Status:
Completed
Trial end date:
2014-05-17
Target enrollment:
Participant gender:
Summary
The purpose of this proof-of-concept study is to assess the safety and effectiveness of
elagolix versus placebo to reduce uterine bleeding associated with uterine fibroids, and to
reduce fibroid volume and uterine volume in premenopausal women 20 to 49 years of age with
heavy uterine bleeding.